person · Reporting owner

MARIO ERNEST

Disclosed activity across 7 companies

Tapewire entity: 90102
SEC CIK: 0001180469

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CHIMERIX INCCMRX · Entity 80651	Director	May 17, 2018	May 21, 2018
HYPERION DEFI, INC.EYEN · Entity 7220	Director	November 17, 2021	November 22, 2021
Jasper Therapeutics, Inc.AMHCU · Entity 7588	Director	November 19, 2019	November 19, 2019
Kindred Biosciences, Inc.KIN · Entity 135544	Director	January 20, 2021	January 22, 2021
SOLENO THERAPEUTICS INCSLNO · Entity 46432	Director	June 06, 2024	June 10, 2024
Tonix Pharmaceuticals Holding Corp.TNXP · Entity 6169	Director	June 25, 2018	June 27, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CHIMERIX INC

Report date May 17, 2018 · Filed May 21, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees	123,167	Reported balance After 2018-05-17 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2018-05-17 · Sale · Disposed 30,000 · Balance 123,167 F1: The range of sale prices received is $4.73 to $4.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
Common StockSEC Table I · non-derivative	IndirectBy The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees	108,167	Reported balance After 2018-05-18 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-05-18 · Sale · Disposed 15,000 · Balance 108,167 F2: The range of sale prices received is $4.76 to $4.84. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
Common StockSEC Table I · non-derivative	Direct	12,905	Reported balance Holding disclosure · report date 2018-05-17 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 12,905

Filing footnotes · ownership attribution and instrument terms

F1: The range of sale prices received is $4.73 to $4.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.

F2: The range of sale prices received is $4.76 to $4.84. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.

HYPERION DEFI, INC.

Report date November 17, 2021 · Filed November 22, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $.0001SEC Table I · non-derivative	Direct	382,706	Reported balance After 2021-11-17 transaction · row 1 1 source row Row 1 · 2021-11-17 · Grant · Acquired 6,963 · Balance 382,706 F1: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.59 · Expires 2031-11-17	Direct	9,653	Reported balance After 2021-11-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-11-17 · Grant · Acquired 9,653 · Balance 9,653 F2: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.

F2: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.

Jasper Therapeutics, Inc.

Report date November 19, 2019 · Filed November 19, 2019

This filing explicitly reported no securities owned.

Kindred Biosciences, Inc.

Report date January 20, 2021 · Filed January 22, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2031-01-19	Direct	49,000	Reported balance After 2021-01-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-01-20 · Grant · Acquired 49,000 · Balance 49,000 F1: The option will vest in four equal quarterly installments from the option grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest in four equal quarterly installments from the option grant date.

SOLENO THERAPEUTICS INC

Report date June 06, 2024 · Filed June 10, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	193,066	Reported balance After 2024-06-06 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2024-06-06 · Grant · Acquired 6,500 · Balance 193,066 F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 6, 2024 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. F2: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
Common StockSEC Table I · non-derivative	IndirectSee footnote	21,789	Reported balance Holding disclosure · report date 2024-06-06 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 21,789 F3: The shares are held by Mildred Mario Nonexempt Trust, of which the Reporting Person is a co-trustee.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 6, 2024 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date.

F2: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

F3: The shares are held by Mildred Mario Nonexempt Trust, of which the Reporting Person is a co-trustee.

Tonix Pharmaceuticals Holding Corp.

Report date June 25, 2018 · Filed June 27, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 par valueSEC Table I · non-derivative	IndirectBy Ernest and Mildred Mario Revocable Trust	50,000	Reported balance After 2018-06-25 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2018-06-25 · Purchase · Acquired 16,500 · Balance 50,000 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.46 to $4.52 per share, inclusive. The reporting person undertakes to provide to Tonix Pharmaceuticals Holding Corp. ("Tonix"), any security holder of Tonix, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.46 to $4.52 per share, inclusive. The reporting person undertakes to provide to Tonix Pharmaceuticals Holding Corp. ("Tonix"), any security holder of Tonix, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CELGENE CORP /DE/

Report date November 20, 2019 · Filed November 22, 2019

Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-11-20 transaction · row 1 1 source row Row 1 · 2019-11-20 · Disposition to issuer · Disposed 62,884 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
Common StockSEC Table I · non-derivative	IndirectFamily Trust	Reported balance After 2019-11-20 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2019-11-20 · Disposition to issuer · Disposed 4,908 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.50 · Expires 2024-07-01	Direct	Reported balance After 2019-11-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-11-20 · Disposition to issuer · Disposed 20,700 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $112.16 · Expires 2025-06-17	Direct	Reported balance After 2019-11-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-11-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.98 · Expires 2026-06-15	Direct	Reported balance After 2019-11-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-11-20 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $121.04 · Expires 2027-06-14	Direct	Reported balance After 2019-11-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-11-20 · Disposition to issuer · Disposed 10,500 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.38 · Expires 2028-06-13	Direct	Reported balance After 2019-11-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-11-20 · Disposition to issuer · Disposed 13,266 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-11-20 · Disposition to issuer · Disposed 300 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-11-20 · Disposition to issuer · Disposed 970 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-11-20 · Disposition to issuer · Disposed 4,756 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.

F2: This option was fully exercisable.

F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.

F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 15, 2018 Filed May 16, 2018 14:46 UTC	CHIMERIX INC CMRX · Entity 80651	SaleCommon Stock	30,000	$4.69	$140,808.00	Disclosure SEC source: 0001209191-18-030453 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees Disclosed balance after: 183,167 F1 · price: The range of sale prices received is $4.55 to $4.78. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document
May 14, 2018 Filed May 15, 2018 15:41 UTC	CHIMERIX INC CMRX · Entity 80651	SaleCommon Stock	22,553	$4.67	$105,232.30	Disclosure SEC source: 0001209191-18-030167 · doc4.xml · nonDerivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees Disclosed balance after: 213,167 F3 · price: The range of sale prices received is $4.6 to $4.76. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document
May 11, 2018 Filed May 15, 2018 15:41 UTC	CHIMERIX INC CMRX · Entity 80651	SaleCommon Stock	22,857	$4.63	$105,766.20	Disclosure SEC source: 0001209191-18-030167 · doc4.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees Disclosed balance after: 235,720 F2 · price: The range of sale prices received is $4.60 to $4.665. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document
May 11, 2018 Filed May 15, 2018 15:41 UTC	CHIMERIX INC CMRX · Entity 80651	SaleCommon Stock	7,143	$4.57	$32,614.22	Disclosure SEC source: 0001209191-18-030167 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees Disclosed balance after: 258,577 F1 · price: The range of sale prices received is $4.505 to $4.59. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document
May 10, 2018 Filed May 11, 2018 17:25 UTC	CHIMERIX INC CMRX · Entity 80651	SaleCommon Stock	2,815	$4.60	$12,949.00	Disclosure SEC source: 0001209191-18-029639 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees Disclosed balance after: 265,720 F1 · price: The range of sale prices received is $4.59 to $4.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document
April 20, 2018 Filed Apr 24, 2018 20:02 UTC	Kindred Biosciences, Inc. KIN · Entity 135544	GrantStock Option (Right to Buy) · Derivative	44,603	$0.00 Strike: $9.65	$0.00	Disclosure SEC source: 0001250853-18-000067 · primary_doc.xml · derivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,603 Underlying: Common Stock · 44,603 shares Expires 2028-04-19 F1 · derivative.exercise_date: The option will vest in four quarterly installments following April 2, 2018. Read SEC document
February 23, 2018 Filed Feb 26, 2018 16:11 UTC	CELGENE CORP /DE/ CELG · Entity 15781	SaleCommon Stock	13,370	$94.49	$1,263,297.88	Disclosure SEC source: 0001209191-18-013316 · doc4.xml · nonDerivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,404 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $94.45 to $94.54, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
February 14, 2018 Filed Feb 26, 2018 16:11 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GiftCommon Stock	2,250	$0.00	$0.00	Disclosure SEC source: 0001209191-18-013316 · doc4.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 324 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document
February 14, 2018 Filed Feb 26, 2018 16:11 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GiftCommon Stock	2,250	$0.00	$0.00	Disclosure SEC source: 0001209191-18-013316 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,774 Read SEC document
February 09, 2018 Filed Mar 9, 2018 15:32 UTC	Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169	GiftCommon Stock, $0.001 par value	10,000	$0.00	$0.00	Disclosure SEC source: 0001615774-18-001750 · s109297_form4.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ernest and Mildred Mario Revocable Trust Disclosed balance after: 33,500 Read SEC document
February 09, 2018 Filed Mar 9, 2018 15:32 UTC	Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169	GiftCommon Stock, $0.001 par value	10,000	$0.00	$0.00	Disclosure SEC source: 0001615774-18-001750 · s109297_form4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document
February 05, 2018 Filed Feb 7, 2018 20:12 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantCommon Stock	8,689	$1.73	$14,999.82	Disclosure SEC source: 0000899243-18-003166 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 704,352 F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis. F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on February 2, 2018, or $1.7263. Read SEC document
January 29, 2018 Filed May 21, 2019 17:24 UTC	HYPERION DEFI, INC. EYEN · Entity 7220	PurchaseCommon Stock, par value $.0001	90,000	$10.00	$900,000.00	Disclosure SEC source: 0001638599-19-000539 · doc4_6117.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,770 Read SEC document
December 21, 2017 Filed Dec 22, 2017 16:58 UTC	Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169	SaleCommon Stock, $0.001 par value	5,000	$3.46	$17,300.00	Disclosure SEC source: 0001615774-17-007572 · s108529_form4.xml · nonDerivative · entry 6 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ernest and Mildred Mario Revocable Trust Disclosed balance after: 23,500 F1 · price: The volume weighted average purchase price of common stock sold by the reporting person in open market transactions on the transaction date. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F7 · price: The range of sale prices on the transaction date was $3.410 to $3.500 per share. Read SEC document
December 20, 2017 Filed Dec 22, 2017 16:58 UTC	Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169	SaleCommon Stock, $0.001 par value	8,965	$3.44	$30,839.60	Disclosure SEC source: 0001615774-17-007572 · s108529_form4.xml · nonDerivative · entry 5 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ernest and Mildred Mario Revocable Trust Disclosed balance after: 28,500 F1 · price: The volume weighted average purchase price of common stock sold by the reporting person in open market transactions on the transaction date. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F6 · price: The range of sale prices on the transaction date was $3.400 to $3.510 per share. Read SEC document
December 19, 2017 Filed Dec 22, 2017 16:58 UTC	Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169	SaleCommon Stock, $0.001 par value	6,035	$3.51	$21,182.85	Disclosure SEC source: 0001615774-17-007572 · s108529_form4.xml · nonDerivative · entry 4 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ernest and Mildred Mario Revocable Trust Disclosed balance after: 37,465 F1 · price: The volume weighted average purchase price of common stock sold by the reporting person in open market transactions on the transaction date. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F5 · price: The range of sale prices on the transaction date was $3.458 to $3.571 per share. Read SEC document
December 18, 2017 Filed Dec 22, 2017 16:58 UTC	Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169	SaleCommon Stock, $0.001 par value	10,000	$3.57	$35,700.00	Disclosure SEC source: 0001615774-17-007572 · s108529_form4.xml · nonDerivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ernest and Mildred Mario Revocable Trust Disclosed balance after: 43,500 F1 · price: The volume weighted average purchase price of common stock sold by the reporting person in open market transactions on the transaction date. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F4 · price: The range of sale prices on the transaction date was $3.510 to $3.605 per share. Read SEC document
December 15, 2017 Filed Dec 22, 2017 16:58 UTC	Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169	SaleCommon Stock, $0.001 par value	5,000	$3.55	$17,750.00	Disclosure SEC source: 0001615774-17-007572 · s108529_form4.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ernest and Mildred Mario Revocable Trust Disclosed balance after: 53,500 F1 · price: The volume weighted average purchase price of common stock sold by the reporting person in open market transactions on the transaction date. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F3 · price: The range of sale prices on the transaction date was $3.520 to $3.650 per share. Read SEC document
December 14, 2017 Filed Dec 22, 2017 16:58 UTC	Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169	SaleCommon Stock, $0.001 par value	1,967	$3.58	$7,041.86	Disclosure SEC source: 0001615774-17-007572 · s108529_form4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ernest and Mildred Mario Revocable Trust Disclosed balance after: 55,467 F1 · price: The volume weighted average purchase price of common stock sold by the reporting person in open market transactions on the transaction date. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. F2 · price: The range of sale prices on the transaction date was $3.530 to $3.610 per share. Read SEC document
October 30, 2017 Filed Nov 1, 2017 16:11 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionStock Option (right to buy) · Derivative	13,600	$0.00 Strike: $31.80	$0.00	Disclosure SEC source: 0001209191-17-058590 · doc4.xml · derivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,600 shares Expires 2022-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan). F2 · derivative.exercise_date: The option was fully exercisable. Read SEC document
October 30, 2017 Filed Nov 1, 2017 16:11 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	13,600	$31.80	$432,412.00	Disclosure SEC source: 0001209191-17-058590 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 02, 2017 Filed Oct 4, 2017 18:03 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantCommon Stock	28,846	$0.52	$14,999.92	Disclosure SEC source: 0000899243-17-023578 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,873,174 F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis. F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on September 29, 2017, or $0.52. Read SEC document
August 10, 2017 Filed Aug 14, 2017 16:53 UTC	CELGENE CORP /DE/ CELG · Entity 15781	SaleCommon Stock	18,506	$130.52	$2,415,403.12	Disclosure SEC source: 0001209191-17-048779 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,424 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $130.00 to $131.59, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document
July 16, 2017 Filed Jul 17, 2017 20:56 UTC	SOLENO THERAPEUTICS INC SLNO · Entity 46432	GrantCommon Stock	24,590	$0.61	$14,999.90	Disclosure SEC source: 0000899243-17-018366 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,844,328 F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis. F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on July 6, 2017, or $0.61. Read SEC document
July 01, 2017 Filed Jul 5, 2017 19:33 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionRestricted Stock Unit · Derivative	734	$0.00	$0.00	Disclosure SEC source: 0001209191-17-043768 · doc4.xml · derivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 734 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on July 1, 2014 vested and such vested portion of the restricted stock units settled for shares of the Company's common stock. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F4 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan (as amended and restated on April 15, 2015)). F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on July 1, 2014 vested and such vested portion of the restricted stock units settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on July 1, 2014 vested and such vested portion of the restricted stock units settled for shares of the Company's common stock. Read SEC document
July 01, 2017 Filed Jul 5, 2017 19:33 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	734	$0.00	$0.00	Disclosure SEC source: 0001209191-17-043768 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on July 1, 2014 vested and such vested portion of the restricted stock units settled for shares of the Company's common stock. Read SEC document
June 30, 2017 Filed Jun 30, 2017 20:55 UTC	Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169	SaleCommon Stock, $0.001 par value	6,105	$4.28	$26,117.19	Disclosure SEC source: 0001615774-17-003462 · s106736_form4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ernest and Mildred Mario Revocable Trust Disclosed balance after: 5,895 F1 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $4.327801965601966. The range of sale prices on the transaction date was $4.25 to $4.29 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. Read SEC document
June 28, 2017 Filed Jun 29, 2017 16:18 UTC	CHIMERIX INC CMRX · Entity 80651	GrantStock Option (Right to Buy) · Derivative	6,341	$0.00 Strike: $5.53	$0.00	Disclosure SEC source: 0001209191-17-042280 · doc4.xml · derivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,341 Underlying: Common Stock · 6,341 shares Expires 2027-06-27 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2018 annual stockholder meeting. Read SEC document
June 28, 2017 Filed Jun 29, 2017 16:18 UTC	CHIMERIX INC CMRX · Entity 80651	GrantStock Option (Right to Buy) · Derivative	21,000	$0.00 Strike: $5.53	$0.00	Disclosure SEC source: 0001209191-17-042280 · doc4.xml · derivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2027-06-27 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2018 annual stockholder meeting. Read SEC document
June 20, 2017 Filed Jun 21, 2017 17:00 UTC	Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169	GrantStock Option · Derivative	20,000	$0.00 Strike: $4.18	$0.00	Disclosure SEC source: 0001615774-17-003296 · s106638_form4.xml · derivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-20 F1 · price: The option was granted pursuant to the Issuer's 2017 Stock Incentive Plan. Read SEC document
June 17, 2017 Filed Jun 20, 2017 16:09 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionRestricted Stock Unit · Derivative	333	$0.00	$0.00	Disclosure SEC source: 0001209191-17-041072 · doc4.xml · derivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334 Underlying: Common Stock · 333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_price: The balance of the restricted stock units will vest on June 17, 2018. Vested shares will be delivered to the reporting person promptly after the vesting date. F5 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan (as amended and restated on April 15, 2015)). F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. Read SEC document
June 17, 2017 Filed Jun 20, 2017 16:09 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	333	$0.00	$0.00	Disclosure SEC source: 0001209191-17-041072 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. Read SEC document
June 15, 2017 Filed Jun 16, 2017 16:11 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionRestricted Stock Unit · Derivative	375	$0.00	$0.00	Disclosure SEC source: 0001209191-17-040464 · doc4.xml · derivative · entry 6 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Underlying: Common Stock · 375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F8 · derivative.exercise_price: The remainder of the restricted stock units will vest as follows: 375 shares on June 15, 2018; 375 shares on June 15, 2019. Vested shares will be delivered to the reporting person promptly after the vesting date. F7 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document
June 15, 2017 Filed Jun 16, 2017 16:11 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	375	$0.00	$0.00	Disclosure SEC source: 0001209191-17-040464 · doc4.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document
June 14, 2017 Filed Jun 16, 2017 16:11 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantRestricted Stock Unit · Derivative	900	$0.00	$0.00	Disclosure SEC source: 0001209191-17-040464 · doc4.xml · derivative · entry 5 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 Underlying: Common Stock · 900 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F7 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F6 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments commencing on June 14, 2018. Vested shares will be delivered to the reporting person promptly after the vesting date. F6 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments commencing on June 14, 2018. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document
June 14, 2017 Filed Jun 16, 2017 16:11 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantStock Option (right to buy) · Derivative	10,500	$0.00 Strike: $121.04	$0.00	Disclosure SEC source: 0001209191-17-040464 · doc4.xml · derivative · entry 4 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2027-06-14 F4 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F3 · derivative.exercise_date: Option is immediately exercisable and will vest on the earlier of June 14, 2018 or the day preceding the date of the next annual stockholder meeting. Read SEC document
May 27, 2017 Filed Mar 9, 2018 15:32 UTC	Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169	Exercise / conversionRestricted Stock Units · Derivative	750	$0.00	$0.00	Disclosure SEC source: 0001615774-18-001750 · s109297_form4.xml · derivative · entry 6 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On May 27, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date. F2 · derivative.expiration_date: On May 27, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date. Read SEC document
May 27, 2017 Filed Mar 9, 2018 15:32 UTC	Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169	Exercise / conversionCommon Stock, $0.001 par value	750	$0.00	$0.00	Disclosure SEC source: 0001615774-18-001750 · s109297_form4.xml · nonDerivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
May 08, 2017 Filed May 9, 2017 16:33 UTC	SOLENO THERAPEUTICS INC CAPN · Entity 46432	GrantEmployee stock option (right to buy) · Derivative	45,139	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0000899243-17-012477 · doc4.xml · derivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,139 Underlying: Common Stock · 45,139 shares Expires 2027-05-08 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary on the Vesting Commencement Date (which is May 8, 2017) or the date of the 2018 Annual Shareholder Meeting, whichever is earlier. Read SEC document
April 07, 2017 Filed Apr 13, 2017 21:28 UTC	SOLENO THERAPEUTICS INC CAPN · Entity 46432	GrantCommon Stock	23,809	$0.63	$14,999.67	Disclosure SEC source: 0000899243-17-010284 · doc4.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,819,738 F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer'scommon stock, on a quarterly basis. F3 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on April 7, 2017, or $0.63. Read SEC document
February 27, 2017 Filed Aug 31, 2017 16:03 UTC	CELGENE CORP /DE/ CELG · Entity 15781	SaleCommon Stock	12,000	$121.24	$1,454,880.00	Disclosure SEC source: 0001209191-17-050872 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,424 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $121.19 to $121.33, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · balance_after: The number of shares reported in Column 5 is inclusive of all transactions subsequent to the February 27, 2017 transaction reported on this Form 4. Read SEC document
February 09, 2017 Filed Mar 9, 2018 15:32 UTC	Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169	Exercise / conversionRestricted Stock Units · Derivative	750	$0.00	$0.00	Disclosure SEC source: 0001615774-18-001750 · s109297_form4.xml · derivative · entry 7 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On February 9, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date. F3 · derivative.expiration_date: On February 9, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date. Read SEC document
February 09, 2017 Filed Mar 9, 2018 15:32 UTC	Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169	Exercise / conversionCommon Stock, $0.001 par value	750	$0.00	$0.00	Disclosure SEC source: 0001615774-18-001750 · s109297_form4.xml · nonDerivative · entry 4 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
February 01, 2017 Filed Jun 16, 2017 16:11 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GiftCommon Stock	3,570	$0.00	$0.00	Disclosure SEC source: 0001209191-17-040464 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,488 Read SEC document
January 23, 2017 Filed Apr 13, 2017 21:28 UTC	SOLENO THERAPEUTICS INC CAPN · Entity 46432	GrantCommon Stock	16,667	$0.90	$15,000.30	Disclosure SEC source: 0000899243-17-010284 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,795,929 F1 · shares: Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer'scommon stock, on a quarterly basis. F2 · price: The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on January 23, 2017, or $0.90. Read SEC document
December 28, 2016 Filed Dec 29, 2016 16:03 UTC	CHIMERIX INC CMRX · Entity 80651	SaleCommon Stock	20,291	$4.52	$91,634.16	Disclosure SEC source: 0001209191-16-156999 · doc4.xml · nonDerivative · entry 4 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees Disclosed balance after: 268,535 F7 · price: The range of sale prices received is $4.51 to $4.5201. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. F8 · ownership.direct: 20,291 shares held by Reporting Person were inadvertently reported on the prior Form 4 as held directly. Instead an aggregate of 20,291 shares previously reported on Form 4 were held by the Reporting Person indirectly in the name of his trust. Read SEC document
December 28, 2016 Filed Dec 29, 2016 16:03 UTC	CHIMERIX INC CMRX · Entity 80651	SaleCommon Stock	4,000	$4.67	$18,682.80	Disclosure SEC source: 0001209191-16-156999 · doc4.xml · nonDerivative · entry 3 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees Disclosed balance after: 288,826 F5 · price: The range of sale prices received is $4.67 to $4.675. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. F6 · ownership.direct: 4,000 shares held by Reporting Person were inadvertently reported on the prior Form 4 as held directly. Instead an aggregate of 4,000 shares previously reported on Form 4 were held by the Reporting Person indirectly in the name of his trust. Read SEC document
December 27, 2016 Filed Dec 29, 2016 16:03 UTC	CHIMERIX INC CMRX · Entity 80651	SaleCommon Stock	3,636	$4.65	$16,907.40	Disclosure SEC source: 0001209191-16-156999 · doc4.xml · nonDerivative · entry 2 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees Disclosed balance after: 292,826 F4 · ownership.direct: 3,636 shares held by Reporting Person were inadvertently reported on the prior Form 4 as held directly. Instead an aggregate of 3,636 shares previously reported on Form 4 were held by the Reporting Person indirectly in the name of his trust. Read SEC document
December 27, 2016 Filed Dec 29, 2016 16:03 UTC	CHIMERIX INC CMRX · Entity 80651	SaleCommon Stock	72,073	$4.68	$337,143.08	Disclosure SEC source: 0001209191-16-156999 · doc4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Ernest and Mildred Mario Revocable Trust, Ernest and Mildred Mario, Trustees Disclosed balance after: 296,462 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on September 15, 2014. F2 · price: The range of sale prices received is $4.65 to $4.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. F3 · ownership.direct: 72,073 shares held by Reporting Person were inadvertently reported on the prior Form 4 as held directly. Instead an aggregate of 72,073 shares previously reported on Form 4 were held by the Reporting Person indirectly in the name of his trust. Read SEC document
November 23, 2016 Filed Nov 28, 2016 11:34 UTC	Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169	PurchaseCommon Stock, $0.001 par value	120,000	$0.41	$48,600.00	Disclosure SEC source: 0001615774-16-008600 · s104797_form4.xml · nonDerivative · entry 1 MARIO ERNEST · CIK 0001180469 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ernest and Mildred Mario Revocable Trust Disclosed balance after: 120,000 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.